Prospective assessment of donor blood screening for antibody to hepatitis C virus and high-titer antibody to hepatitis B core antigen as a means of preventing post-transfusion hepatitis
โ Scribed by Takano, Susumu ;Omata, Masao ;Ohto, Masao ;Nakamura, Kozo
- Publisher
- Springer-Verlag
- Year
- 1993
- Tongue
- English
- Weight
- 315 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0435-1339
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
heart surgery at out institution were prospectively studied. Inclusion crit,eria were the following: absence of transfusion or acute hepatitis during the prior year, alcohol intake <80 gm per day. absence of the use of hepatotoxic drugs, normal aminotransferase values and negative hepatitis B virus
In November 1989, the Japanese Red Cross began transfusion. [4][5][6] In December 1989, first-generation hepscreening blood donors for the hepatitis C virus antiatitis C virus antibodies (anti-HCV) to detect the antibody (anti-HCV) by first-generation assay and high-titer body against nonstructural
Routine screening of blood donors for anti-hepatitis C virus (HCV) has been implemented in most developed countries. However, the independent efficacy of such screening has not been established in a controlled, prospective study. We tracked 478 patients transfused with anti-HCV-negative blood by fir
Prophylactic therapy is generally used to prevent reactivated hepatitis B after transplantation of an antibody to hepatitis B core antigen (anti-HBc)-positive liver. To gain insight into current practice, a questionnaire was e-mailed to 89 liver transplant physicians in the United States, Europe, an